Silence Therapeutics appoints Dr. Steven Romano as a Non-Executive Director
July 29, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that further to the announcements on 18 July 2019 detailing the Company’s collaboration with and equity investment by Mallinckrodt plc (NYSE: MNK), Steven Romano, MD, has today joined the Board of Silence as a Non-Executive Director.
Dr. Steven Romano is executive vice president and chief scientific officer at Mallinckrodt Pharmaceuticals and was appointed a non-executive director of Silence Therapeutics plc in July 2019. At Mallinckrodt, Dr. Romano has executive responsibility for research and development (R&D), medical affairs and regulatory affairs functions and is a member of Mallinckrodt’s executive committee.
Dr. Romano is a board-certified psychiatrist with more than 20 years of experience in the pharmaceutical industry. Prior to joining Mallinckrodt, Dr. Romano spent 16 years at Pfizer, Inc. where he held a series of senior medical and R&D roles of increasing responsibility, culminating in his most recent position as SVP, Head, Global Medicines Development, Global Innovative Pharmaceuticals Business. Prior to joining Pfizer, he spent four years at Eli Lilly.
After receiving his A.B. in Biology from Washington University in St. Louis and his medical degree from the University of Missouri-Columbia, Dr. Romano completed his residency and fellowship at New York Hospital-Cornell Medical Center, continuing on the faculty of the medical school for six additional years.
Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:
“I’m very pleased to welcome Dr. Steven Romano to our Board of Directors. With his executive responsibility for research and development (R&D), medical affairs and regulatory affairs functions at Mallinckrodt, Steve brings wealth of experience that is highly relevant to the current stages of development of Silence’s assets.”
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
Full name and age: Steven Joseph Romano (aged 60)
Current Directorships:
Steven Romano does not currently hold any shares in Silence.
There are no other disclosures required in connection with the appointment of Steven Romano under Schedule Two, paragraph (g) of the Aim Rules for Companies.
Enquiries:
|
Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer |
Tel: +44 (0)20 3457 6900 |
|
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson |
Tel: +44 (0)20 7418 8900 |
|
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray |
Tel: +44 (0) 20 3709 5700 |
|
US IR Westwicke Partners Peter Vozzo |
Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
For more information, please visit: https://www.silence-